Mizuho Securities USA’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Mizuho Securities USA’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16,700	Closed	-$402K	–	180
2019 Q2	$402K	Buy	+16,700	New	+$424K	0.02%	123
2019 Q1	–	Sell	-60,500	Closed	-$1.18M	–	151
2018 Q4	$1.18M	Buy	60,500 +33,500	+124%	+$657K	0.16%	72
2018 Q3	$529K	Buy	+27,000	New	+$513K	0.04%	117

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mizuho Securities USA's HZNP Position: Q3 2019 in Review

Mizuho Securities USA sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019, closing a stake of 16,700 shares — an estimated $402K sold.

Mizuho Securities USA first reported a position in HZNP in Q3 2018 and held it in 3 quarters. The position peaked at $1.18M in Q4 2018. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

Mizuho Securities USA reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2019 after selling out during the quarter.
Mizuho Securities USA sold 16,700 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2019, an estimated $402K.
Mizuho Securities USA first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 3 quarters.
Mizuho Securities USA's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.18M in Q4 2018.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Mizuho Securities USA's 13F filing for Q3 2019, filed 31 Oct 2019.